Pharmaceutical Pricing and Reimbursement Information

231 Pages·2006·4.8 MB·English

PPRI
Pharmaceutical Pricing and Reimbursement Information
A project funded by
European Commission, Directorate-General Health and Consumer Protection and
Federal Ministry of Health and Women's Issues, Austria
INTERIM REPORT
Vienna, May 2006

PPRI

Pharmaceutical Pricing and Reimbursement Information
TECHNICAL INTERIM REPORT
delivered by the main beneficiary

ÖBIG / Austrian Health Institute

ÖBIG / Austrian Health Institute
List of Contents
Abbreviations........................................................................................................................................VIII
Technical Fact sheet...............................................................................................................................IX
1 Introduction.........................................................................................................................................1
2 Overview on PPRI project..................................................................................................................2
2.1 Background..............................................................................................................................2
2.2 Objectives.................................................................................................................................2
2.2.1 General Objectives......................................................................................................2
2.2.2 Specific Objectives.......................................................................................................3
2.3 Commissioners.........................................................................................................................3
2.4 Project Co-ordination................................................................................................................3
2.5 Tasks and Deliverables............................................................................................................5
2.6 Time-table................................................................................................................................6
3 Work package 1: Co-ordination..........................................................................................................7
3.1 Overview..................................................................................................................................7
3.2 Tasks Performed......................................................................................................................7
3.2.1 Network of Partners and Observers............................................................................7
3.2.2 Co-operation between main and associate beneficiary.............................................10
3.2.3 Co-ordination meetings..............................................................................................11
3.2.3.1 Vienna Meeting.............................................................................................11
3.2.3.2 Copenhagen Meeting....................................................................................11
3.2.4 PPRI Intranet Platform...............................................................................................12
3.2.5 Forum of EU funded projects on pharmaceuticals....................................................13
3.3 Work Programme Planned.....................................................................................................14
3.3.1 Further co-ordination meetings..................................................................................14
3.3.2 Regular communication.............................................................................................14
3.3.3 Reporting....................................................................................................................14
4 Work package 2: Dissemination.......................................................................................................15
4.1 Overview................................................................................................................................15
4.2 Tasks Performed....................................................................................................................15
4.2.1 Logo ......................................................................................................................15
4.2.2 Information Leaflet.....................................................................................................16
4.2.3 Website......................................................................................................................16
4.2.4 Communication to commissioning parties.................................................................17
4.2.5 Communication to stakeholders................................................................................17
4.2.6 Presentations at international conferences................................................................18
4.2.7 Articles ......................................................................................................................20
4.3 Work Programme Planned.....................................................................................................21
V
ÖBIG / Austrian Health Institute
4.3.1 Communication and presentations............................................................................21
4.3.2 Publications................................................................................................................21
4.3.3 PPRI Conference.......................................................................................................21
5 Work package 3: Assessment..........................................................................................................22
5.1 Overview................................................................................................................................22
5.2 Tasks Performed....................................................................................................................22
5.2.1 First Assessment Round............................................................................................22
5.2.2 Needs Assessment Guide.........................................................................................23
5.2.3 Needs Assessment....................................................................................................23
5.2.4 Needs Assessment Report........................................................................................24
5.3 Work Programme Planned.....................................................................................................25
6 Work package 4: Survey..................................................................................................................26
6.1 Overview................................................................................................................................26
6.2 Tasks Performed....................................................................................................................26
6.2.1 Template....................................................................................................................26
6.2.2 Style sheet.................................................................................................................30
6.2.3 Glossary.....................................................................................................................30
6.2.4 Editorial Team............................................................................................................31
6.3 Work Programme Planned.....................................................................................................31
6.3.1 Drafting of the Pharma Profiles..................................................................................31
6.3.2 Review of the Template.............................................................................................32
6.3.3 Editorial Work.............................................................................................................32
7 Work package 5: Development of comparable indicators................................................................33
7.1 Overview................................................................................................................................33
7.2 Tasks Performed....................................................................................................................33
7.2.1 Co-operation forum with indicators experts...............................................................33
7.3 Work Programme Planned.....................................................................................................34
7.3.1 Identification and discussion of indicators.................................................................34
7.3.2 Final Set of Benchmarks............................................................................................34
8 Work package 6: Comparative analysis...........................................................................................35
8.1 Overview................................................................................................................................35
8.2 Tasks Performed....................................................................................................................35
8.3 Work Programme Planned.....................................................................................................35

VI
ÖBIG / Austrian Health Institute
List of tables and figures

Table 2.1: Overview - PPRI team at ÖBG......................................................................................4
Table 2.2: Overview - Objectives, work packages and deliverables..............................................5
Table 2.3: Overview - Time-table on PPRI project.........................................................................6
Table 3.1: Work package 1 - Partners and observers participating in the PPRI project,
as of May 2006...............................................................................................................9
Table 4.1: Work package 2 - Presentations on PPRI until beginning of May2006.......................18
Table 4.2: Work package 2 - Articles on PPRI till end-April 2005.................................................20
Table 5.1: Work package 3 - Overview of the key results of the needs assessment...................24
Table 6.1: Work package 4 - Headings of the pharma profiles, as foreseen in the template.......27

VII
ÖBIG / Austrian Health Institute
Abbreviations
AIFA Italian Medicines Agency
BMGF Austrian Federal Ministry of Health and Women's Issues (Österreichisches Bundesministe-
rium für Gesundheit und Frauen)
DG Entr Directorate-General Enterprise and Industry of the European Commission
DG Sanco Directorate-General Health and Consumer Protection of the European Commission
EC European Commission
EGA European Generics Association
EMEA European Medicines Agency
ESIP European Social Insurance Platform
EU European Union
FASII Austrian Federal Association of Social Insurance Institutions
IFPMA International Federation of Pharmaceuticals Manufacturer Associations
LSE London School of Economics
MEDEV Medicine Evaluation Committee
MS Member States
ÖBIG Österreichisches Bundesinstitut für Gesundheitswesen / Austrian Health Institute
OECD Organisation for Economic Co-operation and Development
PGEU Pharmaceutical Group of the European Union
WHO World Health Organisation
WHO Europe World Health Organisation - Regional Office for Europe
WP Work Package
VIII
ÖBIG / Austrian Health Institute
Technical Fact sheet
Project Pharmaceutical Pricing and Reimbursement Information
(PPRI)
Project No. Agreement Number - 2004125
Programme Public Health Programme 2003-2008; Health information
and knowledge 2004
Action Improving information and knowledge for the development
of public health
Start Date of Project April 2005
Duration 24 months
extension to summer 2007 planned
Objectives Improvement of information and knowledge on the phar-
maceutical systems in the enlarged Europe, thus
(cid:127) contributing to increase transparency,
(cid:127) providing information and advice for policy-makers on
national and European levels,
(cid:127) and facilitation a regular exchange of information and
allowing a process of lessons learning from each other.
Tasks/Work packages WP 1 Coordination
WP 2 Dissemination
WP 3 Assessment
WP 4 Survey
WP 5 Development of comparable indicators (bench-
marks)
WP 6 Comparative analysis (benchmarking)
Commissioners (cid:127) European Commission – Health & Consumer Protec-
tion Directorate General
(cid:127) Austrian Ministry of Health and Women’s Issues
DG SANCO Representative Mr. Daniel Mann successor of Ms. Zinta Podniece
Austrian BMGF Representative Mr. Gernot Spanninger
Main Beneficiary Österreichisches Bundesinstitut für Gesundheitswesen /
Austrian Health Institute (ÖBIG)
Associate Beneficiary World Health Organisation – Regional Office for Europe
(WHO Europe)
Partners (cid:127) Ministry of Economy Affairs, Belgium
(cid:127) International Healthcare and Health Insurance Institute,
Bulgaria
(cid:127) Health Insurance Organisation, Cyprus
(cid:127) Ministry of Health, Cyprus
(cid:127) Ministry of Health, Czech Republic
(cid:127) Medicines Agency, Denmark
(cid:127) Ministry of Social Affairs, Estonia
(cid:127) Association of Finnish Pharmacies, Finland
(cid:127) University Claude Bernard Lyon 1, France
(cid:127) Institute for Medical Documentation and Information,
IX
ÖBIG / Austrian Health Institute
Germany
(cid:127) Institute for Pharmaceutical Research and Technology,
Greece
(cid:127) National Health Insurance Fund, Hungary
(cid:127) HSE-Shared Services-Primary Care, Ireland
(cid:127) Medicines Agency, Italy
(cid:127) Ministry of Health, Lithuania
(cid:127) Ministry of Health, Welfare and Sport, Netherlands
(cid:127) Ministry of Health, Poland
(cid:127) State Institute for Drug Control, Slovakia
(cid:127) Agency for Medical Products, Slovenia
(cid:127) Pharmaceutical Benefits Board, Sweden
Institutions involved as Observers National stakeholders
(cid:127) Federal Association of Social Insurance Institutions,
Austria
(cid:127) Health Canada, Canada
(cid:127) Ministry of Health, Cyprus
(cid:127) Charles University, Czech Republic
(cid:127) Ministry of Social Affairs and Health, Finland
(cid:127) National Sickness Fund for Employees, France
(cid:127) National Centre for Pharmaco-economics St. James
Hospital, Ireland
(cid:127) Medicine’s Pricing and Reimbursement Agency, Latvia
(cid:127) Ministry of Economic, Luxembourg
(cid:127) Union of Sickness Funds, Luxembourg
(cid:127) Ministry of Health, Health Division, Malta
(cid:127) Medicines Agency, Norway
(cid:127) Ministry of Health and Care Services, Norway
(cid:127) National Pharmacy and Medicines Institute, Portugal
(cid:127) Ministry of Health and Consumer Affairs, Spain
(cid:127) Andalusian School of Public Health, Spain
(cid:127) Medicines Pharmacy and Industry, United Kingdom

European / International Institutions
(cid:127) Health Division, OECD
(cid:127) European Medicines Agency, EMEA
(cid:127) European Observatory on Healthcare Systems and
Policies
(cid:127) European Commission, DG Enterprise
(cid:127) SOGETI
X